JP5116092B2 - プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物 - Google Patents

プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物 Download PDF

Info

Publication number: JP5116092B2
Authority: JP; Japan
Prior art keywords: aliphatic; substituted; optionally substituted; compound; optionally
Prior art date: 2004-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2007532549A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008513488A5 (pl

JP2008513488A (ja

Inventor

フランチェスコジー．サリトゥロ，

マークダブリュー．レデボーア，

ブライアンレッドフォード，

チァンワン，

アルバートシー．ピアース，

ジョンピー．ダフィ，

デイビッドメッサースミス，

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-17

Filing date

2005-09-19

Publication date

2013-01-09

2005-09-19 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2008-05-01 Publication of JP2008513488A publication Critical patent/JP2008513488A/ja

2008-10-16 Publication of JP2008513488A5 publication Critical patent/JP2008513488A5/ja

2013-01-09 Application granted granted Critical

2013-01-09 Publication of JP5116092B2 publication Critical patent/JP5116092B2/ja

2025-09-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

0 C*N1CCOCC1 Chemical compound C*N1CCOCC1 0.000 description 5
WMFUPWQKKKBMQC-CALCHBBNSA-N CC(C)NC(Nc(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(N(C[C@H]2C)C[C@H](C)N2C(C)=O)c1)=O Chemical compound CC(C)NC(Nc(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(N(C[C@H]2C)C[C@H](C)N2C(C)=O)c1)=O WMFUPWQKKKBMQC-CALCHBBNSA-N 0.000 description 1
MYNSYCVCAPTGHA-UHFFFAOYSA-N CC(Nc(cc1)ccc1Nc(nc1N)n[n]1-c1cc(Cl)ncc1)=O Chemical compound CC(Nc(cc1)ccc1Nc(nc1N)n[n]1-c1cc(Cl)ncc1)=O MYNSYCVCAPTGHA-UHFFFAOYSA-N 0.000 description 1
VPKIAULJSDXMHU-UHFFFAOYSA-N CCOC(N(CC1)CCN1c(cc1)ccc1N/C(/Oc1ccccc1)=N/C#N)=O Chemical compound CCOC(N(CC1)CCN1c(cc1)ccc1N/C(/Oc1ccccc1)=N/C#N)=O VPKIAULJSDXMHU-UHFFFAOYSA-N 0.000 description 1
QFHLZUDZRHUNHP-UHFFFAOYSA-N CCOC(N(CC1)CCN1c(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(Cl)c1)=O Chemical compound CCOC(N(CC1)CCN1c(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(Cl)c1)=O QFHLZUDZRHUNHP-UHFFFAOYSA-N 0.000 description 1
NBZMFUYTOVYXGL-BGYRXZFFSA-N CCOC(N(CC1)CCN1c(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(N(C[C@H]2C)C[C@H](C)N2C(C)=O)c1)=O Chemical compound CCOC(N(CC1)CCN1c(cc1)ccc1Nc(nc1N)n[n]1-c1ccnc(N(C[C@H]2C)C[C@H](C)N2C(C)=O)c1)=O NBZMFUYTOVYXGL-BGYRXZFFSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
JOFRAPLLCNYMLE-OKILXGFUSA-N C[C@H](CN(C[C@@H]1C)c2cc(-[n]3nc(Nc(cc4)ccc4N)nc3N)ccn2)N1C(C)=O Chemical compound C[C@H](CN(C[C@@H]1C)c2cc(-[n]3nc(Nc(cc4)ccc4N)nc3N)ccn2)N1C(C)=O JOFRAPLLCNYMLE-OKILXGFUSA-N 0.000 description 1
APOJIILNJVLCQE-KNVOCYPGSA-N C[C@H]1O[C@@H](C)CN(C)C1 Chemical compound C[C@H]1O[C@@H](C)CN(C)C1 APOJIILNJVLCQE-KNVOCYPGSA-N 0.000 description 1
YCFQPRVUXPTFON-UHFFFAOYSA-N NNc1ccnc(Cl)c1 Chemical compound NNc1ccnc(Cl)c1 YCFQPRVUXPTFON-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP2007532549A 2004-09-17 2005-09-19 プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物 Expired - Fee Related JP5116092B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61090204P	2004-09-17	2004-09-17
US60/610,902		2004-09-17
PCT/US2005/033333 WO2006034116A1 (en)	2004-09-17	2005-09-19	Diaminotriazole compounds useful as protein kinase inhibitors

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2008222676A Division JP2009019048A (ja)	2004-09-17	2008-08-29	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物

Publications (3)

Publication Number	Publication Date
JP2008513488A JP2008513488A (ja)	2008-05-01
JP2008513488A5 JP2008513488A5 (pl)	2008-10-16
JP5116092B2 true JP5116092B2 (ja)	2013-01-09

Family

ID=35583429

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2007532549A Expired - Fee Related JP5116092B2 (ja)	2004-09-17	2005-09-19	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物
JP2008222676A Withdrawn JP2009019048A (ja)	2004-09-17	2008-08-29	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物
JP2013024247A Pending JP2013082756A (ja)	2004-09-17	2013-02-12	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2008222676A Withdrawn JP2009019048A (ja)	2004-09-17	2008-08-29	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物
JP2013024247A Pending JP2013082756A (ja)	2004-09-17	2013-02-12	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物

Country Status (22)

Country	Link
US (1)	US7329652B2 (pl)
EP (1)	EP1791830B1 (pl)
JP (3)	JP5116092B2 (pl)
KR (1)	KR20070057955A (pl)
CN (1)	CN101039933B (pl)
AT (1)	ATE493401T1 (pl)
AU (1)	AU2005286968A1 (pl)
CA (1)	CA2580610C (pl)
CY (1)	CY1112253T1 (pl)
DE (1)	DE602005025655D1 (pl)
DK (1)	DK1791830T3 (pl)
ES (1)	ES2359007T3 (pl)
IL (1)	IL181987A0 (pl)
MX (1)	MX2007003154A (pl)
NO (1)	NO20071915L (pl)
NZ (1)	NZ580450A (pl)
PL (1)	PL1791830T3 (pl)
PT (1)	PT1791830E (pl)
RU (1)	RU2443700C2 (pl)
SI (1)	SI1791830T1 (pl)
WO (1)	WO2006034116A1 (pl)
ZA (1)	ZA200702645B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007305016B2 (en) *	2006-10-02	2011-11-03	Novartis Ag	Compounds and compositions as protein kinase inhibitors
ES2406930T3 (es)	2006-12-29	2013-06-10	Rigel Pharmaceuticals, Inc.	Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
RS53281B (sr) *	2006-12-29	2014-08-29	Rigel Pharmaceuticals Inc.	Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
AU2016259396B2 (en) *	2006-12-29	2018-11-08	Rigel Pharmaceuticals, Inc.	Substituted triazoles useful as Axl inhibitors
CA2710051C (en)	2006-12-29	2017-05-16	Rigel Pharmaceuticals, Inc.	Substituted triazoles useful as axl inhibitors
AU2014200824B2 (en) *	2006-12-29	2016-12-15	Rigel Pharmaceuticals, Inc.	Substituted triazoles useful as Axl inhibitors
CN101622248B (zh)	2006-12-29	2013-04-17	里格尔制药公司	用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑
CA2710230C (en) *	2006-12-29	2016-02-23	Rigel Pharmaceuticals, Inc.	Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI0813356A2 (pt) *	2007-06-15	2014-12-30	Irm Llc	Inibidores de proteína quinase e métodos para uso dos mesmos
JP2011500625A (ja) *	2007-10-18	2011-01-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	トリ置換された１，２，４−トリアゾール
JO2784B1 (en) *	2007-10-18	2014-03-15	شركة جانسين فارماسوتيكا ان. في	5,3,1 - Triazole substitute derivative
CA2704052C (en)	2007-10-26	2015-04-21	Rigel Pharmaceuticals, Inc.	Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
AR070936A1 (es) *	2008-03-19	2010-05-12	Janssen Pharmaceutica Nv	1,2,4 -triazoles trisustituidos
JP5486591B2 (ja) *	2008-05-09	2014-05-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2730251C (en)	2008-07-09	2016-08-09	Rigel Pharmaceuticals, Inc.	Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI1007046B1 (pt)	2009-01-16	2019-07-16	Rigel Pharmaceuticals, Inc.	Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
NZ597453A (en) *	2009-06-09	2013-03-28	Actelion Pharmaceuticals Ltd	Fluorinated aminotriazole derivatives as alxr agonists
TW201204360A (en) *	2010-04-20	2012-02-01	Ab Science	Treatment of multiple sclerosis with MASITINIB
SG11201406584TA (en)	2012-04-24	2014-11-27	Vertex Pharma	Dna-pk inhibitors
WO2014013014A1 (en)	2012-07-18	2014-01-23	Fundació Privada Centre De Regulació Genòmica (Crg)	Jak inhibitors for activation of epidermal stem cell populations
RS62649B1 (sr)	2013-03-12	2021-12-31	Vertex Pharma	Inhibitori dnk-pk
KR102411227B1 (ko)	2013-10-17	2022-06-21	버텍스 파마슈티칼스 인코포레이티드	Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
WO2018041989A1 (en)	2016-09-02	2018-03-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating refractory celiac disease type 2
MX394860B (es)	2016-09-27	2025-03-24	Vertex Pharma	Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
CA3129665A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en)	2019-04-16	2020-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
KR102133595B1 (ko)	2019-05-31	2020-07-13	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 헤테로고리 화합물
KR102112336B1 (ko)	2019-08-12	2020-05-18	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 헤테로고리 화합물
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20250283174A1 (en)	2022-05-16	2025-09-11	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
WO2026093435A1 (en)	2024-10-31	2026-05-07	Institut National de la Santé et de la Recherche Médicale	Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5637592A (en) *	1994-07-12	1997-06-10	Janssen Pharmaceutica N.V.	Acyl derivatives of azolones
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
CN1100777C (zh) *	1997-02-19	2003-02-05	伯莱克斯实验室公司	作为nos抑制剂的n－杂环衍生物
RU2340611C2 (ru) *	2000-09-15	2008-12-10	Вертекс Фармасьютикалз Инкорпорейтед	Производные пиразола, используемые в качестве ингибиторов протеинкиназы
CN1665808A (zh)	2002-05-06	2005-09-07	沃泰克斯药物股份有限公司	噻二唑或噁二唑及其作为jak蛋白激酶抑制剂的用途
AR042052A1 (es) *	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
AU2003293376A1 (en) *	2002-12-10	2004-06-30	Imclone Systems Incorporated	Anti-angiogenic compounds and their use in cancer treatment
ATE455546T1 (de) *	2003-08-06	2010-02-15	Vertex Pharma	Aminotriazol-verbindungen als proteinkinase- hemmer

2005
- 2005-09-19 PT PT05799808T patent/PT1791830E/pt unknown
- 2005-09-19 JP JP2007532549A patent/JP5116092B2/ja not_active Expired - Fee Related
- 2005-09-19 CA CA2580610A patent/CA2580610C/en not_active Expired - Fee Related
- 2005-09-19 ZA ZA200702645A patent/ZA200702645B/xx unknown
- 2005-09-19 RU RU2007114293/04A patent/RU2443700C2/ru not_active IP Right Cessation
- 2005-09-19 PL PL05799808T patent/PL1791830T3/pl unknown
- 2005-09-19 MX MX2007003154A patent/MX2007003154A/es active IP Right Grant
- 2005-09-19 DE DE602005025655T patent/DE602005025655D1/de not_active Expired - Lifetime
- 2005-09-19 NZ NZ580450A patent/NZ580450A/en not_active IP Right Cessation
- 2005-09-19 WO PCT/US2005/033333 patent/WO2006034116A1/en not_active Ceased
- 2005-09-19 US US11/230,221 patent/US7329652B2/en not_active Expired - Fee Related
- 2005-09-19 ES ES05799808T patent/ES2359007T3/es not_active Expired - Lifetime
- 2005-09-19 AU AU2005286968A patent/AU2005286968A1/en not_active Abandoned
- 2005-09-19 CN CN2005800353178A patent/CN101039933B/zh not_active Expired - Fee Related
- 2005-09-19 AT AT05799808T patent/ATE493401T1/de active
- 2005-09-19 SI SI200531255T patent/SI1791830T1/sl unknown
- 2005-09-19 KR KR1020077008732A patent/KR20070057955A/ko not_active Ceased
- 2005-09-19 EP EP05799808A patent/EP1791830B1/en not_active Expired - Lifetime
- 2005-09-19 DK DK05799808.0T patent/DK1791830T3/da active
2007
- 2007-03-18 IL IL181987A patent/IL181987A0/en unknown
- 2007-04-16 NO NO20071915A patent/NO20071915L/no not_active Application Discontinuation
2008
- 2008-08-29 JP JP2008222676A patent/JP2009019048A/ja not_active Withdrawn
2011
- 2011-03-24 CY CY20111100321T patent/CY1112253T1/el unknown
2013
- 2013-02-12 JP JP2013024247A patent/JP2013082756A/ja active Pending

Also Published As

Publication number	Publication date
SI1791830T1 (sl)	2011-05-31
NO20071915L (no)	2007-05-18
KR20070057955A (ko)	2007-06-07
US7329652B2 (en)	2008-02-12
PT1791830E (pt)	2011-04-04
JP2009019048A (ja)	2009-01-29
CA2580610A1 (en)	2006-03-30
CN101039933A (zh)	2007-09-19
CA2580610C (en)	2013-07-09
NZ580450A (en)	2011-06-30
ES2359007T3 (es)	2011-05-17
WO2006034116A1 (en)	2006-03-30
MX2007003154A (es)	2007-05-15
RU2007114293A (ru)	2008-10-27
PL1791830T3 (pl)	2011-05-31
EP1791830B1 (en)	2010-12-29
ZA200702645B (en)	2008-08-27
AU2005286968A1 (en)	2006-03-30
US20060063756A1 (en)	2006-03-23
DK1791830T3 (da)	2011-04-18
DE602005025655D1 (de)	2011-02-10
EP1791830A1 (en)	2007-06-06
CN101039933B (zh)	2012-06-06
IL181987A0 (en)	2007-07-04
JP2008513488A (ja)	2008-05-01
JP2013082756A (ja)	2013-05-09
CY1112253T1 (el)	2015-12-09
RU2443700C2 (ru)	2012-02-27
ATE493401T1 (de)	2011-01-15

Legal Events

Date	Code	Title	Description
2008-08-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080829
2008-08-30	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080829
2011-12-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111215
2012-03-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120314
2012-03-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120322
2012-04-14	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120413
2012-04-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120420
2012-05-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120514
2012-05-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120521
2012-06-16	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120615
2012-10-05	TRDD	Decision of grant or rejection written
2012-10-12	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121011
2012-10-18	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-10-25	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121012
2012-10-26	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-10-29	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20151026 Year of fee payment: 3
2015-10-26	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP2009019048A (ja)	2009-01-29	プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物
JP2008513488A5 (pl)	2008-10-16
US8741912B2 (en)	2014-06-03	Deazapurines useful as inhibitors of Janus kinases
JP5227032B2 (ja)	2013-07-03	プロテインキナーゼの阻害剤として有用なピロロピリミジン
EP1485376B1 (en)	2007-06-27	Compositions useful as inhibitors of protein kinases
US7091343B2 (en)	2006-08-15	Compositions useful as inhibitors of protein kinases
EP1485380B1 (en)	2010-05-19	Azolylaminoazines as inhibitors of protein kinases
EP1485381B1 (en)	2009-06-17	Azolylaminoazine as inhibitors of protein kinases
US20060122185A1 (en)	2006-06-08	Bicyclic inhibitors of Rho kinase
US20040192696A1 (en)	2004-09-30	Compositions useful as inhibitors of protein kinases
JP2008528705A5 (pl)	2009-02-19
AU2007207533A1 (en)	2007-07-26	Azaindoles useful as inhibitors of Janus kinases
AU2012205127B2 (en)	2014-10-30	Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
HK1087700B (en)	2010-09-03	Triazolopyridazines as protein kinases inhibitors
HK1169903A (en)	2013-02-08	Azaindoles useful as inhibitors of janus kinases
HK1135381A (en)	2010-06-04	Deazapurines useful as inhibitors of janus kinases
HK1125632A (en)	2009-08-14	Azaindoles useful as inhibitors of janus kinases